Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial

What Was Tested

Researchers studied Angiotensin II in this clinical study publication.

Catecholamine vasopressors such as norepinephrine are the standard drugs used to maintain mean arterial pressure during liver transplantation.

Angiotensin II is approved for vasodilatory shock but has not been rigorously evaluated for treatment of hypotension during liver transplantation.

Who Took Part

PubMed indexes the participants as adults.

Eligible subjects are adults with a Model for End-Stage Liver Disease Sodium Score ≥25 undergoing deceased donor liver transplantation.

Subjects are randomised 1:1 to receive angiotensin II or saline placebo as the second-line vasopressor infusion.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Angiotensin II.

Some participants received a placebo instead of Angiotensin II, giving a reference point.

Running at several centres spread the Angiotensin II study over different clinics and patient groups.

This is a double-blind, randomised clinical trial.

Secondary outcomes include vasopressin or epinephrine requirement and duration of hypotension.

An intention-to-treat analysis will be performed for all randomised subjects receiving the study drug.

What Was Measured

Angiotensin II is approved for vasodilatory shock but has not been rigorously evaluated for treatment of hypotension during liver transplantation.

PubMed files the paper under topics including Angiotensin II, Liver Transplantation, End Stage Liver Disease, Living Donors, Vasoconstrictor Agents, Hypotension and Norepinephrine.

The authors tagged it with the keywords Blood Pressure and Liver Cirrhosis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.

The publication is from 2023 (BMJ open), a journal based in England.

More context: the Angiotensin II compound page, all human trials.